Year Ended December 31,
2013 2012 $ Change % Change
($ in millions)
Product sales, net:
FUSILEV
$ 68.4 $ 204.3 $ (135.9 ) (66.5 )%
FOLOTYN
44.4 20.4 24.0 >100.0 %
ZEVALIN
29.4 30.3 (0.9 ) (3.0 )%
MARQIBO
1.3 — 1.3 >100.0 %
MARQIBO revenue derived in 2013 is a result of our acquisition of Talon in July 2013. ( July 17, 2013, )
Acquisitions : We completed two strategic acquisitions, including a FDA-approved, patented, proprietary, oncology drug, MARQIBO through the acquisition of a NASDAQ-listed company, Talon Therapeutics, Inc. and we licensed-in a late-stage oncology drug, Captisol-enabled MELPHALAN, from Ligand Pharmaceuticals, Inc.
•
Commercial : We executed the launch of MARQIBO in less than seven weeks after acquisition, and we continued to focus on the growth of our marketed drugs.
so less than 7 week so end september / beginning october
so 1.3 Million in 3 Month selling and we need 30 million / Year for the first payment
The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 3 (x) ). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:
•
1. target
$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year
•
$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year
•
$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year
•
$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year
•
$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year
•
$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion
